INNOVADERM CRO IS NOW INDERO.

8 Advantages of Adaptive Design in Clinical Trials

Diane Potvin

Diane Potvin

Senior Statistical Advisor

Author picture

Explore our latest infographic to get a comprehensive overview of the advantages of adaptive design.

  • Patient Focus
    Limiting patient exposure to drugs or doses that are not sufficiently effective.
  • Trial Efficiency
    Allowing trial completion with fewer patients, enriching the trial population in a subgroup of patients for whom the medication is effective.
  • Early Termination
    Stopping the trial early if the medication is not effective.
  • Optimal Selection
    Selecting a dose, a formulation or a treatment regimen for which the efficacy is good enough to be approved by health authorities.
  • Environmental Impact
    Reducing the environmental impact of clinical research.
  • Power Control
    In contrast, increasing the sample size to maintain or achieve the trial power could also prevent a study from failing for lack of power, and thus, have a better control of the Type 2 error.
  • Sample Size
    Adjusting, especially reducing, the required sample size needed may be crucial for a study conducted in a rare disease, or a disease that is more difficult to recruit due to comorbidities.
  • Dose Range
    Drug developers may study a wider range of doses.

Click this link to download the PDF version.

Read the full article: Potvin D, D’Angelo P, Bennett S, Jankicevic J, Bissonnette R. Adaptive designs in dermatology clinical trials: Current status and future perspectives. J Eur Acad Dermatol Venereol. 2024 Apr 15. doi: 10.1111/jdv.20030. Epub ahead of print. PMID: 38619384.

SHARE THIS POST

Subscribe to our newsletter.

Do not miss out on valuable insights and research updates. Join our scientific community today!

This field is for validation purposes and should be left unchanged.

Jeff Smith

Chef de la direction

Jeff Smith, Chef de la direction d’Indero Recherches, apporte prĂšs de 30 ans d’expĂ©rience dans l’industrie pharmaceutique et CRO, s’Ă©tant distinguĂ© par son leadership exceptionnel, sa vision stratĂ©gique et son innovation. L’expertise de Jeff couvre des opĂ©rations mondiales, la gestion de la croissance, ainsi que la promotion d’une culture d’entreprise collaborative. Ses atouts en matiĂšre de crĂ©ation de valeur, de gestion des partenaires et d’opĂ©rations CRO ont toujours contribuĂ© au succĂšs dans ses fonctions prĂ©cĂ©dentes. Sous la direction de Jeff, Indero continue d’étendre ses capacitĂ©s, faisant progresser les connaissances mĂ©dicales et les nouvelles thĂ©rapies en dermatologie et en rhumatologie.

Revolutionize Your Topical Trials

Efficacy insights in days, not months.

 Indero’s Early Phase 1 model enables sponsors to initiate topical studies that detect early pharmacodynamic signals much sooner than traditional phase 1, using microdosing and transcriptomic analysis. This approach reduces preclinical requirements, shortens study duration from 8–12 weeks to ≀3 days, and lowers costs, helping teams make informed go/no-go decisions faster.